Can a new drug help when standard chemo leaves cancer behind?

NCT ID NCT00877500

Ongoing Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether the drug ixabepilone can help people with HER2-negative breast cancer who still have significant cancer after standard chemotherapy. About 116 participants will either receive ixabepilone or standard care. The goal is to see if ixabepilone improves outcomes and to understand which tumors might respond best.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ixabepilone (a chemotherapy drug that blocks cell division)
What this could lead to: If it works, this could provide a new treatment option for breast cancer patients who still have cancer after initial chemotherapy.
What could go wrong: This is a small, early-phase trial (116 participants) and may not show a clear benefit. Ixabepilone can cause side effects like nerve damage and low blood cell counts.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BILATERAL BREAST CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bilateral breast carcinoma Her2-receptor negative breast cancer invasive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BILATERAL BREAST CARCINOMA HER2/NEU NEGATIVE INVASIVE BREAST CARCINOMA

Contacts and locations

Locations

Advocate Christ Medical Center

Oak Lawn, Illinois, 60453-2699, United States
Lyndon Baines Johnson General Hospital

Houston, Texas, 77026-1967, United States
M D Anderson Cancer Center

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.